BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27930322)

  • 1. Casitas B-cell lymphoma (Cbl) proteins protect mammary epithelial cells from proteotoxicity of active c-Src accumulation.
    Mukhopadhyay C; Triplett A; Bargar T; Heckman C; Wagner KU; Naramura M
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8228-E8237. PubMed ID: 27930322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ubiquitin Ligases c-Cbl and Cbl-b Negatively Regulate Platelet-derived Growth Factor (PDGF) BB-induced Chemotaxis by Affecting PDGF Receptor β (PDGFRβ) Internalization and Signaling.
    Rorsman C; Tsioumpekou M; Heldin CH; Lennartsson J
    J Biol Chem; 2016 May; 291(22):11608-18. PubMed ID: 27048651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
    Nihal M; Wood GS
    Oncotarget; 2016 Aug; 7(33):53869-53880. PubMed ID: 27472394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An essential role of CBL and CBL-B ubiquitin ligases in mammary stem cell maintenance.
    Mohapatra B; Zutshi N; An W; Goetz B; Arya P; Bielecki TA; Mushtaq I; Storck MD; Meza JL; Band V; Band H
    Development; 2017 Mar; 144(6):1072-1086. PubMed ID: 28100467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase.
    Shintani T; Ohara-Waki F; Kitanaka A; Tanaka T; Kubota Y
    Blood Cells Mol Dis; 2014 Dec; 53(4):211-8. PubMed ID: 25084697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway.
    Fasen K; Cerretti DP; Huynh-Do U
    Traffic; 2008 Feb; 9(2):251-66. PubMed ID: 18034775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.
    Calco GN; Stephens OR; Donahue LM; Tsui CC; Pierchala BA
    J Biol Chem; 2014 Mar; 289(11):7307-19. PubMed ID: 24425877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
    Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
    J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A beta 1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration.
    Meng F; Lowell CA
    EMBO J; 1998 Aug; 17(15):4391-403. PubMed ID: 9687507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav.
    Lottin-Divoux S; Jean D; Le Romancer M; Frade R
    Cell Signal; 2006 Aug; 18(8):1219-25. PubMed ID: 16289966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils.
    Melander F; Andersson T; Dib K
    Biochem J; 2003 Mar; 370(Pt 2):687-94. PubMed ID: 12435267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative regulation of Lck by Cbl ubiquitin ligase.
    Rao N; Miyake S; Reddi AL; Douillard P; Ghosh AK; Dodge IL; Zhou P; Fernandes ND; Band H
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3794-9. PubMed ID: 11904433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45.
    Okabe S; Tauchi T; Ohyashiki K; Broxmeyer HE
    Blood Cells Mol Dis; 2006; 36(2):308-14. PubMed ID: 16503409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation.
    Kim M; Tezuka T; Tanaka K; Yamamoto T
    Oncogene; 2004 Mar; 23(9):1645-55. PubMed ID: 14661060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
    Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
    Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation.
    Masson K; Heiss E; Band H; Rönnstrand L
    Biochem J; 2006 Oct; 399(1):59-67. PubMed ID: 16780420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation.
    Elly C; Witte S; Zhang Z; Rosnet O; Lipkowitz S; Altman A; Liu YC
    Oncogene; 1999 Feb; 18(5):1147-56. PubMed ID: 10022120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex.
    Kim J; Kang D; Sun BK; Kim JH; Song JJ
    Cell Signal; 2013 Jan; 25(1):372-9. PubMed ID: 23085457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis.
    Ahmad G; Mohapatra BC; Schulte NA; Nadeau SA; Luan H; Zutshi N; Tom E; Ortega-Cava C; Tu C; Sanada M; Ogawa S; Toews ML; Band V; Band H
    Int J Biochem Cell Biol; 2014 Dec; 57():123-34. PubMed ID: 25449262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.